BJMO - , issue ,
Ronald de Wit; MD
The positive outcome of several randomized clinical trials evaluating immune checkpoint inhibitors in patients with metastatic bladder cancer dramatically changed the treatment paradigm in this setting. In his presentation, Prof. de Wit summarized the clinical data generated with PD-1/PD-L1 inhibitors in this setting, but he kicked off by summarizing the historical results obtained with chemotherapy in patients with metastatic urothelial cancer.
Read moreBJMO - volume 12, issue 10, march 2018
Ronald de Wit; MD , PhD
The positive outcome of several randomized clinical trials evaluating immune checkpoint inhibitors in patients with metastatic bladder cancer dramatically changed the treatment paradigm in this setting. In his presentation, Prof. de Wit summarized the clinical data generated with PD-1/PD-L1 inhibitors in this setting, but he kicked off by summarizing the historical results obtained with chemotherapy in patients with metastatic urothelial cancer.
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.